ABBV
SP100NYSEAbbVie Inc.
Healthcare · Drug Manufacturers - General · United States
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
www.abbvie.com ↗Shares trade at a premium 128.0× trailing earnings, easing to 16.1× on forward estimates. Profitability shows a net margin of 5.8%. Leverage is elevated at 2.1× net debt/EBITDA. Revenue grew 12.4% year-on-year. It yields 2.7% in dividends. The mean analyst target of USD256.14 sits 1.9% below the current price (Buy, 28 analysts).
business model
AbbVie is a research-based biopharmaceutical company that develops, manufactures, and sells branded prescription drugs and some aesthetic products. Revenue comes primarily from patent-protected therapies sold to wholesalers, specialty pharmacies, and providers, with pricing supported by insurers and government payers.
revenue segments
Key franchises include immunology (Skyrizi and Rinvoq, now the growth drivers as Humira faces biosimilar competition), oncology (Imbruvica, Venclexta), neuroscience (Vraylar, Botox Therapeutic, migraine drugs), aesthetics (Botox Cosmetic, Juvederm from the Allergan acquisition), and eye care. The US is the largest market, with meaningful international sales across Europe and other regions.
key dependencies
Dependent on patent exclusivity, a productive R&D and clinical pipeline, and FDA/EMA regulatory approvals. It relies on contract and internal manufacturing, specialty distribution, and reimbursement from commercial and government payers; US drug-pricing policy (including Medicare negotiation under the IRA) is a major macro dependency.
competitors
Competes with other large pharma and biotech firms including Johnson & Johnson, Pfizer, Merck, Bristol-Myers Squibb, Amgen, Novartis, Roche, and Eli Lilly, as well as biosimilar makers of Humira.
moat
Moat stems from patents, regulatory barriers, clinical trial data, established brands, and scale in specialty distribution and sales. The successful transition from Humira to Skyrizi and Rinvoq demonstrates franchise durability, though moats erode as patents expire.
risks
Main risks are the Humira biosimilar erosion, patent cliffs on other products, pipeline/clinical trial failures, drug-pricing reform and payer pressure, litigation, and high acquisition-related debt and goodwill from the Allergan deal.
Financials & metrics
as of 22 Aug 2026Price is closer to the high end of its range. Green = nearer the yearly low, red = nearer the high — a position indicator, not a buy/sell signal.
Tap any metric for an explanation.● provider● computedN/A not available from source
Valuation history is being recorded
We snapshot P/E and price targets daily. This chart fills in over the coming days.
Full financial statements
Income statement
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | $61.16B | $56.33B | $54.32B | $58.05B | — |
| Cost of revenue | $18.20B | $16.90B | $20.41B | $17.41B | — |
| Gross profit | $42.96B | $39.43B | $33.90B | $40.64B | — |
| Operating expense | $22.86B | $27.54B | $20.37B | $21.83B | — |
| R&D | $9.10B | $12.79B | $7.67B | $6.51B | — |
| Operating income | $20.09B | $11.89B | $13.54B | $18.81B | — |
| Interest expense | $2.89B | $2.81B | $2.22B | $2.23B | — |
| Pretax income | $6.60B | $3.72B | $6.25B | $13.48B | — |
| Tax provision | $2.36B | -$570.00M | $1.38B | $1.63B | — |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | — |
| EBITDA | $17.63B | $14.91B | $17.17B | $24.17B | — |
| Diluted EPS | $2.37 | $2.39 | $2.72 | $6.63 | — |
Balance sheet
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $133.96B | $135.16B | $134.71B | $138.81B | — |
| Current assets | $29.06B | $25.58B | $33.00B | $28.46B | — |
| Cash & equivalents | $5.23B | $5.52B | $12.81B | $9.20B | — |
| Inventory | $4.95B | $4.18B | $4.10B | $3.58B | — |
| Total liabilities | $137.19B | $131.80B | $124.31B | $121.52B | — |
| Current liabilities | $43.29B | $38.75B | $37.84B | $29.54B | — |
| Total debt | $67.50B | $67.14B | $59.38B | $63.27B | — |
| Long-term debt | $58.94B | $60.34B | $52.19B | $59.13B | — |
| Shareholders' equity | -$3.27B | $3.33B | $10.36B | $17.25B | — |
| Retained earnings | -$15.49B | -$7.90B | -$1.00B | $4.78B | — |
| Working capital | -$14.23B | -$13.17B | -$4.84B | -$1.07B | — |
Cash flow
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $19.03B | $18.81B | $22.84B | $24.94B | — |
| Investing cash flow | -$6.64B | -$20.82B | -$2.01B | -$623.00M | — |
| Financing cash flow | -$12.72B | -$5.21B | -$17.22B | -$24.80B | — |
| Capital expenditure | -$1.21B | -$974.00M | -$777.00M | -$695.00M | — |
| Free cash flow | $17.82B | $17.83B | $22.06B | $24.25B | — |
| Dividends paid | -$11.66B | -$11.03B | -$10.54B | -$10.04B | — |
| Share buybacks | -$980.00M | -$1.71B | -$1.97B | -$1.49B | — |
| End cash position | $5.23B | $5.52B | $12.81B | $9.20B | — |
Reported figures from public filings via Yahoo Finance. Line coverage varies by company. Not investment advice.
Dividends
Analyst assessment
as of 22 Aug 2026Aggregate consensus only. Named per-analyst targets require a premium source and are not shown; the data model is ready to hold them if one is added.
Technicals
as of 21 Aug 2026News
Sector peers
Notes & alerts
Sign in to keep a private research note and set price alerts for ABBV.